JP2015512387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512387A5 JP2015512387A5 JP2015501721A JP2015501721A JP2015512387A5 JP 2015512387 A5 JP2015512387 A5 JP 2015512387A5 JP 2015501721 A JP2015501721 A JP 2015501721A JP 2015501721 A JP2015501721 A JP 2015501721A JP 2015512387 A5 JP2015512387 A5 JP 2015512387A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- gdf11
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 102100003272 GDF11 Human genes 0.000 claims 27
- 101700065866 GDF11 Proteins 0.000 claims 27
- 229920001184 polypeptide Polymers 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 230000032683 aging Effects 0.000 claims 9
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 4
- 230000000747 cardiac effect Effects 0.000 claims 3
- 208000003017 Aortic Valve Stenosis Diseases 0.000 claims 2
- 206010002906 Aortic stenosis Diseases 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 2
- 210000004556 Brain Anatomy 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 210000004351 Coronary Vessels Anatomy 0.000 claims 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010020871 Hypertrophic cardiomyopathy Diseases 0.000 claims 2
- 210000002027 Muscle, Skeletal Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000000271 cardiovascular Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Claims (30)
- 対象における加齢関連状態を処置するための、GDF11ポリペプチドレベルを増加させる組成物を含む薬学的組成物。
- 加齢関連状態が、心血管状態、心臓の老化、骨格筋の老化、および脳の老化からなる群より選択される、請求項1記載の薬学的組成物。
- 対象が、拡張期心不全、心肥大、加齢関連心肥大、高血圧症、弁膜症、大動脈弁狭窄症、遺伝性肥大型心筋症、または加齢による心臓の硬化からなる群より選択される状態を有するかまたは有すると診断されている、請求項1〜2のいずれか１項に記載の薬学的組成物。
- GDF11ポリペプチドレベルが対象の循環血液中のGDF11レベルである、請求項1〜3のいずれか１項に記載の薬学的組成物。
- GDF11ポリペプチドレベルが、対象の心組織におけるGDF11レベルである、請求項1〜3のいずれか１項に記載の薬学的組成物。
- GDF11ポリペプチドを含む、請求項1〜5のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:14のアミノ酸配列を含むGDF11ポリペプチドを含む、請求項1〜6のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:2のアミノ酸配列を含むGDF11ポリペプチドを含む、請求項1〜6のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:1のアミノ酸配列を含むGDF11ポリペプチドを含む、請求項1〜6のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:15のアミノ酸配列を含むGDF11ポリペプチドを含む、請求項1〜6のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:1、2、14、または15のいずれかのアミノ酸配列を含むGDF11ポリペプチドのホモ二量体を含む、請求項1〜10のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:1、2、14、または15のアミノ酸配列を含むGDF11ポリペプチドの複合体を含む、請求項1〜11のいずれか１項に記載の薬学的組成物。
- GDF11ポリペプチドをコードする核酸を含む、請求項1〜12のいずれか１項に記載の薬学的組成物。
- 静脈内、皮下、動脈内、および冠動脈内からなる群より選択される経路で投与するための、請求項1〜13のいずれか１項に記載の薬学的組成物。
- GDF11レベルが少なくとも100％増加する、請求項1〜14のいずれか１項に記載の薬学的組成物。
- GDF11レベルが健康な参照レベルの少なくとも75％まで増加する、請求項1〜15のいずれか１項に記載の薬学的組成物。
- 単離されたGDF11ポリペプチドおよび薬学的に許容される担体を含む、薬学的組成物。
- 心血管状態、心臓の老化、骨格筋の老化、脳の老化、拡張期心不全、心肥大、加齢関連心肥大、高血圧症、弁膜症、大動脈弁狭窄症、遺伝性肥大型心筋症、または加齢による心臓の硬化からなる群より選択される状態を処置するための、GDF11ポリペプチドを含む薬学的組成物。
- GDF11ポリペプチドが、対象の循環血液中のGDF11レベルを増加させる、請求項18記載の薬学的組成物。
- GDF11ポリペプチドが、対象の心組織におけるGDF11レベルを増加させる、請求項18〜19のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:14のアミノ酸配列を含むGDF11ポリペプチドを含む、請求項18〜20のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:2のアミノ酸配列を含むGDF11ポリペプチドを含む、請求項18〜21のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:1のアミノ酸配列を含むGDF11ポリペプチドを含む、請求項18〜21のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:15のアミノ酸配列を含むGDF11ポリペプチドを含む、請求項18〜21のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:1、2、14、または15のいずれかのアミノ酸配列を含むGDF11ポリペプチドのホモ二量体を含む、請求項18〜24のいずれか１項に記載の薬学的組成物。
- SEQ ID NO:1、2、14、または15のアミノ酸配列を含むGDF11ポリペプチドの複合体を含む、請求項18〜25のいずれか１項に記載の薬学的組成物。
- GDF11ポリペプチドをコードする核酸を含む、請求項18〜26のいずれか１項に記載の薬学的組成物。
- 静脈内、皮下、動脈内、および冠動脈内からなる群より選択される経路で投与するための、請求項18〜27のいずれか１項に記載の薬学的組成物。
- GDF11レベルが少なくとも100％増加する、請求項18〜28のいずれか１項に記載の薬学的組成物。
- GDF11レベルが、健康な参照レベルの少なくとも75％まで増加する、請求項18〜29のいずれか１項に記載の薬学的組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612550P | 2012-03-19 | 2012-03-19 | |
| US61/612,550 | 2012-03-19 | ||
| US201261649962P | 2012-05-22 | 2012-05-22 | |
| US61/649,962 | 2012-05-22 | ||
| PCT/US2013/030140 WO2013142114A1 (en) | 2012-03-19 | 2013-03-11 | Growth differentiation factor (gdf) for treatment of diastolic heart failure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512387A JP2015512387A (ja) | 2015-04-27 |
| JP2015512387A5 true JP2015512387A5 (ja) | 2016-04-07 |
| JP6124986B2 JP6124986B2 (ja) | 2017-05-10 |
Family
ID=49223184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501721A Active JP6124986B2 (ja) | 2012-03-19 | 2013-03-11 | 拡張期心不全を処置するための増殖分化因子（ｇｄｆ） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9434779B2 (ja) |
| EP (1) | EP2828289B1 (ja) |
| JP (1) | JP6124986B2 (ja) |
| CA (1) | CA2901394A1 (ja) |
| ES (1) | ES2779698T3 (ja) |
| WO (1) | WO2013142114A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| AU2011289284B2 (en) | 2010-08-13 | 2015-04-09 | Somalogic Operating Co., Inc. | Pancreatic cancer biomarkers and uses thereof |
| RU2651708C2 (ru) * | 2011-09-30 | 2018-04-23 | Сомалоджик, Инк. | Прогнозирование риска сердечно-сосудистого события и его применение |
| US10092627B2 (en) * | 2013-04-08 | 2018-10-09 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating skeletal muscle stem cells |
| US20160220640A1 (en) * | 2013-06-11 | 2016-08-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for increasing neurogenesis and angiogenesis |
| US10017566B2 (en) | 2013-11-12 | 2018-07-10 | The Brigham And Women's Hospital, Inc. | Growth differentiation factor (GDF) for treatment of diastolic heart failure |
| WO2015176066A2 (en) * | 2014-05-16 | 2015-11-19 | Intermune, Inc. | Lpa-associated protein and rna expression |
| WO2016049662A1 (en) * | 2014-09-23 | 2016-03-31 | President And Fellows Of Harvard College | Methods and compositions for treating age-related disorders |
| JP6768651B2 (ja) | 2014-11-24 | 2020-10-14 | ソマロジック, インコーポレイテッドSomaLogic, Inc. | 増殖分化因子１１と結合するための核酸化合物 |
| US11041006B2 (en) | 2015-12-28 | 2021-06-22 | Riken | Compositions for use in recovering or ameliorating deterioration of physiological functions due to aging |
| CA3010799A1 (en) | 2016-01-06 | 2017-07-13 | President And Fellows Of Harvard College | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
| WO2019144053A1 (en) * | 2018-01-19 | 2019-07-25 | President And Fellows Of Harward College | Gdf11 variants and uses thereof |
| US20200222459A1 (en) * | 2019-01-16 | 2020-07-16 | Melvin Barnes | System, Method and Compositions for Treating Age-Related Illnesses and Conditions |
| JP2022001603A (ja) * | 2021-10-14 | 2022-01-06 | 功 加治佐 | 自分由来ｉＰＳ若い血液応用ＧＤＦ１１分子コーティング若返り経口不老不死薬９ |
| CN114989310A (zh) * | 2022-06-20 | 2022-09-02 | 深圳先进技术研究院 | 一种嵌合抗原受体、表达嵌合抗原受体的巨噬细胞及应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4612302A (en) | 1983-11-14 | 1986-09-16 | Brigham And Women's Hospital | Clinical use of somatostatin analogues |
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| EP1378572B1 (en) * | 1993-05-12 | 2006-10-25 | Genetics Institute, LLC | Bmp-11 compositions |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6008434A (en) * | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| EP1988395A1 (en) | 1997-05-30 | 2008-11-05 | Curis, Inc. | Methods for evaluating tissue morphogenesis and morphogenic activity |
| US20030170213A1 (en) * | 1998-01-23 | 2003-09-11 | Marc F. Charette | Methods and compositions for enhancing cognitive function using morphogenic proteins |
| US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
| US20060078532A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20070155661A1 (en) * | 2003-02-14 | 2007-07-05 | The Board Of Trustees Of The Leland Standord Junior University | Methods and compositions for modulating the development of stem cells |
| NZ529860A (en) | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
| EP1858546A4 (en) | 2005-03-04 | 2009-03-04 | Biorexis Pharmaceutical Corp | MODIFIED TRANSFERRINFUSION PROTEINS |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| JP5362554B2 (ja) | 2006-05-17 | 2013-12-11 | ストライカー コーポレイション | 軟骨の欠損を処置するための可溶性形態形成タンパク質の使用 |
| TWI573802B (zh) * | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| EP2626703B1 (en) | 2008-03-27 | 2017-05-03 | Promega Corporation | Protein labeling with cyanobenzothiazole conjugates |
-
2013
- 2013-03-11 JP JP2015501721A patent/JP6124986B2/ja active Active
- 2013-03-11 US US14/385,578 patent/US9434779B2/en active Active
- 2013-03-11 CA CA2901394A patent/CA2901394A1/en active Pending
- 2013-03-11 WO PCT/US2013/030140 patent/WO2013142114A1/en active Application Filing
- 2013-03-11 EP EP13764561.0A patent/EP2828289B1/en active Active
- 2013-03-11 ES ES13764561T patent/ES2779698T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512387A5 (ja) | ||
| Bonow | New insights into the cardiac natriuretic peptides | |
| DK1728507T3 (da) | Anvendelse af vitamin K for at omvende forkalkning af blodkar | |
| EA201791656A1 (ru) | Соединения 4-метилсульфонилзамещенной пиперидинмочевины для лечения дилатационной кардиомиопатии (dcm) | |
| HEARTS | Clinically significant anatomical variations of the left coronary artery in human cadaveric hearts | |
| JP2015521611A5 (ja) | ||
| RU2592148C1 (ru) | Способ прогнозирования риска развития фибрилляции предсердий после коронарного шунтирования у пациентов с ишемической болезнью сердца | |
| WO2015074010A3 (en) | Compositions and methods for cardiac regeneration | |
| Cooper et al. | Central venous spasm during pacemaker insertion | |
| Pyka et al. | Revascularization in ischemic heart failure with reduced left ventricular ejection fraction. The impact of complete revascularization | |
| Lebedyantseva et al. | Structural abnormalities in periodontal tissues in chronic apical periodontitis | |
| Datta et al. | Apical Hypertrophic Cardiomyopathy and Myocardial Infarction in a Young Adult, a Rare Combination | |
| Rajeshwari | Bilateral absence of common carotid artery with variant branching pattern of aortic arch | |
| Zavalloni et al. | Anomalous origin of the left coronary artery from the pulmonary artery in an adult pregnant patient: surgical and percutaneous myocardial revascularization | |
| Kraiem et al. | P4718 Follow up in heart failure center versus routine practice: which positive impact we can have? | |
| Hayashi et al. | P3293 One year result of the underfilling strategy in transcatheter aortic valve implantation with balloon expandable valve | |
| Madias | Coronary artery systolic “milking” and “bridging” in Takotsubo syndrome: substrate or an epiphenomenon? | |
| Ali | Hypertensive vascular disease | |
| Lyamina et al. | P3427 Molecular markers of ischemia in myocardial cardioprotection assessment in physical rehabilitation programs in cardiac patients | |
| Hieda et al. | Acute effects of adaptive servo-ventilation on hemodynamics in advanced chronic heart failure patients | |
| Fritz et al. | Multivessel myocardial bridging in a patient with spiral hypertrophic cardiomyopathy | |
| Sillanmaki et al. | P1563 Relationships between electrical and mechanical dyssynchrony in patients with left bundle branch block | |
| Nair et al. | Do Continuous Flow LVADS Improve Diastolic Dysfunction? | |
| Struijker-Boudier | Large arteries, microcirculation, and mechanisms of hypertension | |
| Ehara et al. | P3425 Persistence of impaired chronotropic responses after the completion of phase II cardiac rehabilitation predicts a poor long-term cardiovascular prognosis |